Symplmed is a private pharmaceutical company. Symplmed has no securities registered under the United States Securities Act of 1933. Materials contained on this site do not constitute a solicitation, offer or recommendation concerning, or refer in any way to, any sale of securities.

Symplmed is optimizing the value of its medicines and those of its industry partners by streamlining the prescription process, from fulfillment and payment to therapeutic compliance and outcomes monitoring. The Company’s patented technology platform, DyrctAxess, enables direct delivery of medications to a patient’s home and eliminates the problem of unfilled prescriptions. By providing shared access to real-time information about medication use and its efficacy, DyrctAxess helps patients, physicians and manufacturers achieve optimal care.

Symplmed is taking a therapeutic area approach, ensuring that medications necessary to manage a particular disease state are available through its DyrctAxess platform. The Company’s initial focus is high blood pressure (hypertension) with proprietary Prestalia®, a single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate. Symplmed also plans to expand its pipeline in multiple therapeutic areas.